This site is intended for health professionals only

Published on 28 April 2008

Share this story:
Twitter
LinkedIn

AFFiRiS in the spotlight

teaser

According to an analysis carried out by Lifescience-online, due to it’s AFFITOME technology AFFiRiS GmbH could become a major player in the global pharmaceutical industry.

After looking at data from a total of 67 European biotech companies, the study picked out the five firms with the most innovative approaches to therapy and most intensive R&D activities for closer analysis. AFFiRiS GmbH came top of this shortlist.

In the run-up to the international industry trade fair BIO-Europe Spring 2008 in Madrid, the EBDGroup published an exclusive study by Lifescience-online, a wholly-owned subsidiary of the international consultancy firm Lifescience-consulting.

The study, entitled “Spotlight: 5 Promising European Biotech Companies”, showcased five young European biotechnology companies that the authors believe have the potential to become major players on their respective markets.

Listed top of these five companies is AFFiRiS GmbH, whose AFFITOME technology has been singled out as an innovative approach to the treatment of life-threatening diseases such as Alzheimer’s disease and atherosclerosis.

To date, AFFiRiS has used AFFITOME technology to develop two Alzheimer’s vaccines and a granted patent on a hemodialysis method that can be used to treat Alzheimer’s patients.

Both Alzheimer’s vaccines, designated as AD01 and AD02, are currently undergoing clinical phase I trials. These are expected to yield initial results before the end of 2008. So far, all the patients who have been vaccinated have tolerated the treatment extremely well.

Dr Walter Schmidt, CEO of AFFiRiS, on the study’s findings: “Naturally, we are delighted to receive independent recognition for the success of our development programme. It is also worth noting that the analysis did not even take into account our second Alzheimer’s vaccine, which only entered clinical trials a few days ago. In fact, we have already bettered the business development expectations that were mentioned in the analysis.”

AFFiRiS GmbH



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn